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ABSTRACT 
 
Regenerative medicine is a discipline that aims to achieve regeneration of cells, tissue or 
organs in order to restore or establish normal functions. There are several strategies that can 
be used to achieve this goal. Many of the strategies are based on use of genes or cells to 
regenerate organ functions. The present thesis aim to investigate different gene and cell based 
methods for the use in regenerative medicine. 
 
In paper I a novel peptide conjugate is described for the use of gene transfer in vitro and in 
vivo.  It shows that serum-resistant nanoparticles are formed upon co-incubation of Stearyl-
TP10 with plasmid DNA and that these nanoparticles efficiently transfect cells ubiquitously 
with minimal toxicity. It is also shown that stearyl-TP10/plasmid nanoparticles enable 
efficient dose-dependent gene delivery in vivo when being administered intramuscularly or 
intradermally without any associated observed toxicity or induction of immune response. In 
vivo transfection was highly dependent on a specific charge ratio; this stands in contrast to 
the in vitro response. Altogether these results show that stearyl-TP10 is an attractive non 
viral, peptide-based mediator of plasmid delivery, that is effective both in vitro and in vivo. 
This peptide based vector could be adapted for delivery of other nucleic acids. 
 
Paper II investigates natural conditions that allow clonal survival and self-renewal of human 
embryonic stem (ES) cells. Only two laminins, LN-511 and LN-521, could support long-term 
self-renewal of the cells in a completely defined and xeno-free environment but, unlike LN-
511, LN 521 permits survival of individualized human ES or induced pluripotent stem (iPS) 
cells plated at certain densities.  
  
The paper also shows that the use of LN-521 and E-cadherin together as a culture matrix 
supports both derivation and clonal survival of hES cells. The paper demonstrates that a 
single cell obtained by biopsy from an 8-cell human in vitro fertilized (IVF) embryo can give 
rise to new human ES cell lines under completely chemically defined and xeno-free 
conditions. The methods developed here may have significance for research and clinical 
applications of human ES cells or other cell types.  
 
Paper III describes the treatment with messenchymal stromal cells (MSC) in two patients 
with severe refractory ARDS on extracorporeal membrane oxygenation. (ECMO) Although 
no conclusions could be drawn on effectiveness of MSC treatment in ARDS, clinical 
improvement was shown after MSC treatment allowing discontinuation of ECMO support 
and, subsequently, a progressive decrease in the need for mechanical ventilation . Apart 
from monitoring the clinical progress the in vivo actions of the MSCs on lung and systemic 
inflammation are correlated to vitro potency assays, including effects on inflammatory and 
immune modulatory cells. Also proteomic assessments of the MSCs and extra cellular 
vesicles (EV) released by the MSCs are described. This paper outlines a case report and is 
now planned to be expanded in to a phase 1 clinical trial with MSC treatment to ARDS 
patients ECMO support. 
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1 INTRODUCTION 
 
Gene and cell therapy in regenerative medicine 
Gene and cell therapy are overlapping fields of biomedical research aiming at alleviating or 
curing disease by means of genetic or cellular transfer. There are also increasing therapeutic 
strategies combining the two fields in order to improve the therapeutic outcome. 
 
1.1 Gene Therapy 
Historically, the development of DNA recombinant technology in the 1970s provided new 
therapeutic options and laid the foundation for gene therapy. Early in the 70s there were two 
papers that proposed the theory that disease with “Bad DNA” could be cured with exogenous 
replacement of  “Good DNA” (1, 2). Already in Friedmann´s and Roblin´s 1972 paper (2) 
fundamental barriers for gene delivery were discussed and outlined as well as discussions on 
viral and non viral delivery of genetic material. Many of these points are still valid today. 
This gave rise to a long scientific struggle of vector optimization in order to successfully 
transfer new therapeutic genes into recipient cells. In 1990 the technology had matured 
enough to conduct the first clinical experimentation. The affected patients suffered from 
adenosine deaminase deficiency a congenital disease that gives rise to a severe impairment of 
immunity and are thus prone to infections. These first clinical trials utilized viruses as transfer 
vectors due to their superior ability to transfer genetic material into target cells. The results 
were encouraging but only gave a transient effect on the immune reconstitution (3). Inspired 
by these findings numerous clinical trials were started but with the death of Jesse Gelsinger, a 
boy suffering from ornithine transcarbamylase deficiency, and who was enrolled in a gene 
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therapy clinical trial, many trials were put on hold or stopped. Post mortem autopsy 
concluded that the cause of death was systemic response against the adenoviral vector 
administrated in the trial (4). This was followed by an initially promising result of full 
correction in two patients with X1-SCID, a disease that similarly to ADA gives rise to an 
immunodeficiency (5).  The trial was later put on hold when a number of patients showed 
tumor development caused by the gene therapy vector (6). Over the years new vectors with a 
safer profile have been developed and viral-mediated gene therapy has a shown to have very 
good therapeutic effects in several different condition such as primary immunodeficiencies, 
hemophilia, cancer and eye disorders (7-11). Interestingly, the development of a leukemia-
like condition in patients with X1-SCID has never been observed in patients with ADA-
SCID, demonstrating that other parameters than the vector are also important (12). 
 
1.2 Gene therapy principles 
Gene therapy can be carried out using three principle strategies namely, gene addition, gene 
correction and gene knock-down. Gene addition is the most commonly used strategy in gene 
therapy. In principle, a missing gene due to genetic mutation or overexpression of a transgene 
is yielding the therapeutic effect. Genetic correction is possibly the most challenging 
approach from a technical standpoint. It has gained popularity by introduction of zinc-finger 
nucleases and DNA recombination technologies and has been used to create mutations in 
CCR5 to prevent HIV infection (13). Especially the recent development of the CRISPR/Cas 9 
technology has already had a major impact on the field (14). Gene knockdown is built around 
the Nobel Prize winning discovery of RNA interference (15). It takes advantage of different 
RNA species ability to down regulate gene expression and has together with gene correction 
the greatest potential for optimal clinical results 
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1.3 Technical barriers to successful gene therapy 
Gene therapy is conceptually built on vectors that deliver the genetic material. The various 
vectors´ history, creation and use are an entire research field of its own. During the last 
decade improvements in gene transfer into cells or tissue has largely been dependent on 
advances in vector technologies by refining the vectors systems, enhancing 
transduction/transfection efficiencies and improving production and safety profiles of the 
vectors. Although progress has been made there are still hurdles to improve and overcome. 
The main barriers for delivery of genetic material are described below and in Figure 1. 
Figure 1. The main barriers for gene therapy  
1, Uptake, transport and uncoating of the vector. The vector binds to a cellular membrane and is internalized by 
different mechanisms. Most uptake steps involve a ligand and receptor interaction. 2, Most vectors enter the 
endosome and needs to escape in order to avoid degradation. 3, Transport to the nucleus is also required for 
successful therapy and can be achieved during cell division or by active transport. 4, Vector genome is either 
integrated or transcribed extra chromosomal. 5, The immune response against the vector or the transgene product 
can limit the viability of the transduced cells. 
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1.3.1 Cellular uptake, transportation and uncoating of vector 
In order to mediate the therapeutic effect, a gene therapy vector that is administered by local 
or systemic delivery needs to be taken up by the target tissue. Vector distribution is 
influenced by many factors such as vascular supply, endothelial barriers, vector size and 
ligand receptor interactions. Viruses have by evolution developed efficient mechanisms to 
enter the cell and the nucleus, but for non-viral vectors the limiting steps are usually 
endosomal escape and transportation through the nuclear membrane. 
 
1.3.2 Duration of transgene expression.  
Vectors can be expressed either as episomes or integrated in the host genome. Episomal 
vectors will be lost with cell division but can have persistent expression for many years in 
organs with quiescent tissue such as liver or muscle due to that cell divisions are rare (16, 17). 
Vectors that integrate into the host genome have sustained expression even in rapidly 
dividing cells but can potentially activate or disrupt nearby genes by insertional mutagenesis 
(6). Both episomal and integrated vectors can be silenced through epigenetic modifications of 
the vector genome. Ideally one should match the duration of the vector expression to the time 
the vector needs to be expressed to treat a specific disease. Many monogenetic diseases need 
lifelong treatment that can be achieved either by stable duration of vector expression or 
repetitive dosing.  In other diseases such as cancer a shorter transient expression could be 
favorable.  
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1.3.3 The host immune response.    
Both the vector and the product of the transgene could potentially activate an immune 
response. Immune responses can be divided into three types, innate, and adaptive, which can 
be further subdivided into humoral and cell-mediated immune response. Innate response can 
cause local or systemic toxicity. Innate response has been a key issue in gene therapy 
strategies using small RNA molecules (18). Humoral response can be either directed against 
the vector limiting effectiveness or rule out the possibility of re-administration (19, 20). 
Humoral response towards the transgene product can also be problematic but avoiding 
expression of the transgene in antigen presenting cells can lower the risk. Finally, cell 
mediated immune response can eliminate the transduced cells, the response can be directed 
against the vector as well as the transgene (21)  
 
1.4 Non viral gene therapy 
The early successful protocols in gene therapy utilized viral vectors for transfer of the 
therapeutic gene. Although the use of viral vectors have advanced the field of gene therapy 
they have inherent problems in immunogenicity, carcinogenesis, limitation of transgene 
size, and complex vector production (17, 22-24).. Non viral delivery platform has the 
potential to address these limitations, especially in respect to safety. The non viral vectors 
have lower immunogenicity and patients have no pre-excising immunity. Non viral vectors 
are generally easier to produce and are less restricted regarding the transgene size, 
comparison of vectors are outlined in Table 1 (25, 26). As DNA/RNA molecules are too 
large, hydrophilic and negatively charged to diffuse across cell membranes on their own, 
delivery vectors or chemical modifications are generally required to bring the therapeutic 
genetic material to the site of action. This means to the nucleus for plasmids that need to be 
transcribed. If the genetic drug is a RNA species the site of action is in the cytosol. Before 
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the target cell can be reached, the systemically administered genetic material needs to 
overcome a wide range of challenges in the body. The hurdles to overcome are degradation 
by serum endonucleases, evasion of immune detection, and prevention of nonspecific 
interactions with plasma proteins or non-target cells, avoidance of renal clearance, ability to 
extravasate to reach target tissues and promote cell entry. When the target cell is reached 
the genetic drug needs to escape endosomal degradation and facilitate nuclear entry at cell 
division or by active transport as described above. Methods developed to overcome barriers 
for genetic drug delivery include chemical modification, direct injection and the use of 
nanoparticles as carriers. 
Vector Cell type Efficacy 
for in vivo 
gene 
delivery 
Duration of 
expression 
DNA 
carrying 
capacity 
Immunogenic 
response against 
the vector 
Production 
Viral Dividing or 
non-
dividing 
High Stable or 
transient 
<8 Kb Low to high Difficult 
and 
expensive 
Non 
Viral 
Mostly 
dividing 
cells 
Low Mostly 
transient 
>10 Kb Low (mainly) to 
moderate 
Easy and 
not 
expensive 
Table 1. Gene therapy vector characteristics 
 
1.5 Peptide based gene transfer 
Non viral delivery strategies are usually based on complexation of chemical components 
that form complexes with DNA. One such strategy has been to utilize cell penetrating 
peptides (CPPs) that form complexes with DNA by noncovalent electrostatic- and 
hydrophobic interactions. CPPs have been successfully used for carrying different cargoes 
such as plasmids (pDNAs), oligonucleotides and proteins (27). Although CPPs have been 
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reported to enter the cell by direct translocation across the cell membrane, most CPPs enter 
the cell through endocytic pathways. After the compound is internalized into the endosome 
the complex needs to escape degradation.  To overcome this problem many strategies 
aiming at increasing endosomal escape have been investigated (28, 29). One possibility to 
increase the activity of CPPs is to introduce a stearyl moiety. This approach has previously 
been reported to improve polyarginine-mediated delivery of small interfering RNAs and 
plasmids (30-33). However, the stearylation strategy does not seem to provide the same 
effects for all peptides.  
 
1.6 Cell therapy 
Allotransplantation of whole organs has been the classic way to restore damaged organ 
function.  The first transplantation was done by Theodor Kocher that performed a thyroid 
transplantation in 1883 and he was later awarded the Nobel prize in medicine for his 
groundbreaking studies. Today organ transplantation has matured and transplantation of 
organs such as heart, kidney, liver, lungs and intestines are carried out on a routine basis. 
Although effective, the method is limited due to shortage of organs available for 
transplantation and possible immune rejection of allotransplants. The adaptive and innate 
immune systems, mentioned earlier, are the human organism’s defense systems against 
pathogens resulting in that essentially all transplantations from non-identical individuals end 
in rejection of the grafted cells or organs if not prevented by immunosuppression. 
Immunological rejection can be divided into three different categories that are ABO blood 
group antigen, major histocompatibility complex, and minor histocompatibility complex 
rejections (34)  
Cellular therapy comprises of a broad spectrum of strategies in which cells are used in order 
to cure or alleviate disease. Apart from blood transfusions and skin transplantation the first 
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successful use of cells as treatment was done in 1953 by Mathe et al where they demonstrated 
grafting of chimeric bone marrow in a patient accidently exposed to whole-body irradiation.  
They subsequently confirmed the usefulness of this strategy in patients with leukemia that 
had undergone irradiation therapy and could in certain individuals reconstitute hematopoietic 
function by allogenic bone marrow engraftment.  (35, 36) These early experiments have 
developed into accepted clinical practice of a number of hematological disease including 
malignancies, immune deficiencies and inborn errors of metabolisms to name but a few. In 
later years cellular based therapies has focused on the use of stem or progenitor cells to 
amend disease and recover organ function. There are two principal therapeutic mechanisms. 
The first comprises of progenitor or multipotent stem cells for the long-term regeneration of 
damage tissue or function. The second category is that the transplanted cells mediate the 
therapeutic effects by the release of soluble factors such as cytokines, growth factors and 
exosomes. Messenchymal Stromal Cells (MSC) used in treatment of Graft vs Host disease 
folds into this category (37, 38). In later years much research has been done on embryonic 
stem cells and induced pluripotent stem cells that falls into category number one. Schwartz et 
al. reported data on two prospective phase 1/2 studies on subretinal transplantation of hESC-
derived retinal pigment epithelium into 18 patients with macular dystrophy. The underlying 
pathology is caused by degradation of macular cells due to genetic mutations in the retinal 
cells leading to blindness. The initial results are promising showing, no evidence of adverse 
proliferation; transplant rejection or any other serious safety issues regarding the transplanted 
cells. In 10 out of 18 patients there is a significant improvement in eye function, seven 
patients have experienced a modest improvement and only one patient has suffered a decline 
in the eye function (39). Similarly a Japanese woman in her 70s with wet type age-related 
macula degeneration became the first patient to receive tissues derived from human iPSCs in 
September 2014. The underlying pathology is caused by damage of the photoreceptors in the 
eye leading to blindness. The retinal pigment epithelium cells given as an injection into the 
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eye had been derived from autologous human iPSC line generated from the patient’s own 
skin cells. No results from the trial have been reported to date.  
Regardless the cell type or disease several hurdles need to be over come in order to develop 
cell therapy to mainstream clinical treatments. These hurdles include generating sufficient 
number of cells, development of xeno-free culturing methods, reducing tumorgenicity and 
safety issues as well as overcoming immunological barriers to name a few (40).  
 
1.7 In vitro culturing of human cells 
Degenerative diseases, such as Parkinson’s disease, diabetes, congenital eye disease and 
others, as well as severe injuries either completely eliminate entire cellular populations or 
significant fraction of them thus leaving no cellular target for standard medical treatments. 
Therefore, cellular transplantations are warranted to restore function and structure of the 
affected organs  
As a part of a multicellular organism, almost any mammalian cell is intricately controlled by 
molecular cues of the extracellular milieu that include interactions with other cells, 
extracellular matrix molecules, and soluble factors from the bodily fluids. Therefore, in vitro 
culturing environment must provide mammalian cells with essential signals to stay alive, 
proliferate, and preserve (or change if it is needed) cellular identity. Mimicking the natural 
cell environment inside the body is in theory a straightforward way to achieve this goal. For 
instance, extracellular matrix (ECM) proteins that are in contact with certain cells may be 
studied using immunofluorescence methods and appropriate ECM molecules may be later 
used as cell substrata to culture those cells in vitro.  
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1.8 Laminins 
One important class of ECM proteins is laminins (41). They are large heterotrimeric 
glycoproteins containing one α, one β, and one γ chains. Laminins are named after their chain 
composition, for instance laminin-221 (LN-221) consists α2, β2, and γ1 chains (42). Five α 
chains, four β chains, three γ chains, and 16 combinations of them have been discovered in 
humans to date (41). Mutations in laminin chains often lead to embryonic lethality or severe 
diseases (41). Laminins (LNs) are the major part of basement membranes (43). The ECM 
glycoproteins are in direct contact with the majority of cell types in vivo often inducing 
signalling inside cells via interaction with cell membrane receptors. Integrins (44-46), 
dystroglycan (45, 47), Lutheran receptor (48, 49) and sulfated glicolipids (50) are cell 
membrane receptors that bind various laminin isoforms. Apart form direct signalling, 
laminins are capable of co-signalling with other ligands of various kind and polarization of 
cells thus significantly affecting cellular behavior (41). Laminins affect migration, 
proliferation, differentiation, and survival of various cells in the human body. Expression of 
laminins display various spatio-temporal patterns and certain degree of tissue specificity (41), 
for instance LN-211 is specific for muscle and neural tissues, LN-332 is specific to epithelia.  
 
1.9 Sources of cells for regenerative medicine 
Somatic cells isolated from humans undergo senescence with time in culture that limits their 
proliferation potential. Majority of somatic cells expresses high levels of human leukocyte 
antigens (HLAs). Expression of HLAs confers immune rejection of cells after transplantation 
into genetically non-identical individuals (allotransplantations). Therefore, somatic cells are 
not a preferred source of cells for regenerative medicine, especially if the aim is longterm 
engraftment. Various human pluripotent stem cells (hPSCs) exhibit essentially unlimited 
proliferation potential and can provide an almost unlimited number of cells for regenerative 
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medicine (40). Multipotent mesenchymal stromal cells do not induce alloreactive response, at 
least not to a substanial degree. Therefore, these two types of cells are promising sources of 
cells for regenerative medicine. 
 
1.10 Human pluripotent stem cells 
All hPSCs share abilities to proliferate indefinitely and to give rise to all cellular lineages in 
the body. Several types of hPSCs have been described to date (51-54). Human embryonic 
stem cells (hESCs) were first derived in 1998 (51). Human induced pluripotent stem cells 
(hiPSCs) were developed later (52, 55), but they are the most commonly used in the research 
laboratories type of hPSCs at the moment. Development of hiPSC-based clinical treatments 
have been hampered by epigenetic abnormalities as well as other factors difficulties (40).  
The ability to proliferate indefinitely, differentiate into all somatic cellular lineages, and low 
rate of epigenetic abnormalities are the main advantages of hESCs that are still considered as 
‘gold standard’ hPSCs and are already used in several clinical trials (39, 40). Since hESCs are 
usually derived from the inner cell masses of human blastocysts, they are ethically 
controversial and allogeneic to patients. Only supernumerary in vitro fertilized (IVF) 
blastocysts that cannot be used in infertility treatments with informed consent of the both 
donors are used to derive new hESC lines (56). Nevertheless, the procedure demands 
destruction of human embryos, which is an important ethical concern. Derivation of hESC 
lines from a single cell (blastomere) biopsy of a human 8-cell embryo can address the ethical 
concern of many (57). Acquisition of a blastomere does not interfere with developmental 
potential of the embryo and is a standard procedure that is used in in vitro fertilization clinics 
during treatment of pairs with certain genetic backgrounds.  
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Although different in some important details, hPSCs exhibit many common features and are 
cultured using same methods. In the past, hPSCs were cultured on a layer of feeder cells (51) 
(usually murine or human fibroblasts) or on Matrigel (58). The latter is a protein preparation 
from Engelbreth–Holm–Swarm mouse sarcoma. Matrigel is a complex mixture of ECM 
proteins and growth factors that are bound to them. Both feeders and Matrigel are batch-to-
batch variable, chemically undefined substrata that pose a risk of contamination with 
infectious adventitious agents or induction of undesired immunogenicity in hPSCs cultured 
on them. Therefore, culturing of hPSCs involving feeder cells or Matrigel is unreliable and 
may be unsafe. Preferably, development of cells aimed at therapeutic applications should be 
done under chemically defined and animal product-free (xeno-free) conditions. Several such 
methods, which may significantly facilitate development of clinical treatments involving 
hPSCs, have been reported to date (59-62). 
 
1.11  Multipotent mesenchymal stromal cells 
Multipotent MSCs are isolated from bone marrow, fat and other tissues (63). At the moment 
they are defined by the ability to adhere to cell-culture treated plastic, expression, or lack of 
expression of certain markers (CD73+, CD90+, CD105+, CD11b-, CD14-, CD34-, CD45-, 
CD19-, CD79-a, and HLA-DR-) and the ability to differentiate into adipocytes, osteoblasts, 
and chondrocytes in vitro showing multipotency (64). Importantly, individual mesenchymal 
stromal cells exhibit different levels of multipotency suggesting heterogeneity of MSC 
populations (65). Apart from multipotency, MSCs exhibit strong immunomodulatory 
properties (63). This feature has given rise to many preclinical and clinical studies on 
treatment of various immune and inflammatory diseases with MSCs (38, 66-68). In many 
cases, the therapy has shown significant efficacy but the exact molecular mechanism of the 
action is not entirely clear. Although MSCs are capable of homing to sites of injury, there is 
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little proof for long-term incorporation into the recipient’s tissues suggesting that paracrine 
mechanisms are the main mode of action. Antidonor immune responses in allo-MSC 
transplantations have been reported in preclinical models (69) and can potentially explain 
the fast clearance and low engraftment (69). However no adverse events has been reported 
related to an antidonor immune response in clinical trials (70). 
Interestingly, MSC may exhibit both immunosuppressive and immunoactivation properties 
depending on signals from the extracellular milieu (71). It has been surmised that circulating 
factors in the particular patient at the time of infusion define pro- or anti-inflammatory 
properties of the MSCs (72) . Toll-like receptors on the MSC surface can bind bacterial 
products such as lipopolysaccharide (LPS) from the local milieu and induce expression of 
pro-inflammatory factors TNFα, IL-6, IL-8, and others (73) by the MSCs. On the other hand, 
the immunosuppressive phenotype of MSC is induced by contact with pro-inflammatory 
cytokines from the environment (74). In human MSCs, INFγ–induced expression of 
indoleamine 2,3-dioxygenase (IDO) enzyme has been shown to mediate inhibition of T-cells 
by inducing apoptosis in them (75, 76). Other mechanisms that do not rely of IDO expression 
have been also described (77). Expression of prostaglandin E2 (PGE2) by MSCs in response 
to inflammatory cytokines IFNγ and TNFα has been shown to promote both pro- and anti-
inflammatory effects depending on the PGE2 concentration and other factors from the local 
environment (78, 79). An important example is the induction of T regulatory cells, which are 
pivotal for suppression of immune reactions, by PGE2 expressed by MSCs (80). Another 
interesting mediator is Human leukocyte antigen-G (HLA-G), known for its tolerogenic and 
potent immune inhibitory function, exists in seven different isoforms, of which the full-
length transmembrane HLA-G1, and its soluble counterpart HLA-G5, are the most 
extensively studied (81, 82). Both HLA-G1 and HLA-G5 are potent suppressors of 
allogeneic T-cell response through induction of CD8+ T-cell apoptosis and arrest of T- and 
B-cell proliferation, inhibitors of natural killer cell cytotoxicity, they can also induce T 
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regulatory cells (83) (84). MSC have been shown to constitutively express HLA-G at low 
levels (83). Recently, microRNAs (miRNAs) have been identified as an additional factor of 
the milieu that may affect expression of various proteins in MSCs or may be released by 
MSCs (85).  
 
Paracrine factors that are released by MSCs may affect both nearby cells and cells situated at 
large distances. Extracellular vesicles (EV) including exosomes that are small structures 
encapsulated into lipid bi-layer and released by cells mediate the delivery of the paracrine 
factors at large distances (86). EVs have been shown to interact with cell receptors via 
molecules on their surfaces and to merge their content with the recipient cells thus delivering 
the paracrine factors. Interestingly, MSC-EVs themselves, without MSCs of origin, have 
exhibited the therapeutic potential in various preclinical studies (87). Figure 2 outlines some 
of the factors and cells MSC are believed to affect to yield a therapeutic response.  
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Figure 2. MSC mechanistic environment 
It is a complex mechanistic environment that is involved in MSCs’ therapeutic response. This involves soluble 
factors as IDO, PGE, HLA-G5, IL-6 and extracellular vesicles that affect immune cells.  
 
1.12 Extracorporeal membrane oxygenation 
Extracorporeal membrane oxygenation (ECMO) is a technique to provide advanced support 
to patients with heart and lung failure. The ECMO circuit is removing blood from the 
patient’s body and removes carbone dioxide and oxygenates the red blood cells before 
pumping the blood back to the patient. The technique was develop from Gibbons heart and 
lung machine and was first demonstrated in infants undergoing heart surgery for congenital 
heart defects (88, 89). In 1976 the first report on successful use of ECMO in respiratory 
failure was demonstrated in neonates with severe respiratory distress (90). Although 
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primarily developed for neonatal support ECMO has become more popular as support 
therapy in the adult population.  The two most common types of ECMO are veno-venous 
(VV) and veno-arterial (VA) ECMO. In both types the blood is drained from the venous site 
and in VV ECMO the blood is returned on the venous site whereas in VA ECMO the blood is 
returned to the arterial site. The use of VV ECMO is more popular in pulmonary failure and 
VA ECMO more in heart failure. 
 
1.13 Acute respiratory distress syndrome 
Acute respiratory distress syndrome is caused by direct or indirect damage to the lungs. 
Direct causes are viral or bacterial pneumonia, aspiration pneumonia, chest trauma or 
inhalation of toxic fumes. Indirect causes comprise of systemic processes such as sepsis, 
pancreatitis, serial transfusions or multiple trauma. Diagnostic criteria using the Berlin 
definition is presented in Table 2. Although debuting with respiratory failure it can develop 
into a multiorgan failure affecting other organs such as the liver and kidney. A number of 
different pharmacologic therapies have failed to demonstrate benefit and treatment is 
currently limited to supportive care using low tidal volume mechanical ventilation and fluid 
management (91, 92). The addition of extracorporeal membrane oxygenation (ECMO) has 
been used in patients with severe ARDS, however, in a recent systematic review and meta-
analysis of current evidence, no association with improved outcomes could be demonstrated 
in adult patients (93). 
ARDS is characterized by severe acute inflammatory response in the lung. This gives rise to 
damage of the alveolar-capillary barrier and the resulting oedema hampers the gas-exchange. 
Early mortality in ARDS is frequently caused by hypoxia/anoxia and after two weeks the 
mortalities are more attributed to pulmonary fibrosis, nosocomial infections and multiorgan 
failures (94).  The pathology is not fully understood, but what is known is that early on there 
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is a loss in capillary endothelial cells as well as type 1 alveolar cells and protein rich oedema 
is then flooding the alveolar and interstitial space .The epithelium is then replaced by hyaline 
membranes.  Neutrophils invade the damaged tissue and adhere to the activated endothelium 
and polymorphonuclear leukocytes/neutrophils further damage the lung with the release of 
proteolytic enzymes, oxidants and reactive nitrogen species. The release of chemokines also 
induces the migration of macrophages that release cytokines and apoptosis inducing ligands. 
Within 3 days the secondary fibroproliferative phase starts with infiltration of fibroblast as 
well as of mesenchymal progenitor cells. Loss of type 1 pneumocytes occurs and this cell 
type is replaced by type 2 pneumocytes and fibrin is accumulated due to reduced fibronolytic 
activity. The matrix composition is also changed with replacement of type III collagen with 
type I collagen. This leads to a fibrotic and stiff lung (95). There is currently no animal model 
for ARDS but there are several models of acute lung injury, the most common ones being 
based on lipopolysaccharide or Bleomycin.. 
Non-HLA matched, mesenchymal stromal cells (MSCs) have been 
demonstrated to be safe and potentially effective in different  clinical applications (96-99). In 
several preclinical models of acute lung injury MSCs have demonstrated therapeutic potential 
(96, 100-106). While not fully understood, the mechanisms of MSC actions in acute models 
of ARDS include the release of paracrine anti-inflammatory and anti-bacterial peptides and 
mitochondrial transfer through cell-cell contact with damaged alveolar epithelial cells (102, 
107-109). Additionally, MSCs release extracellular vesicles that can reduce inflammation and 
promote tissue regeneration in different pre-clinical models (110-113). Due to the beneficial 
safety profile of non-HLA matched allogeneic MSCs in combination with scientific 
publications demonstrating promising results in a widening range of clinical applications in 
both lung diseases as well as other diseases (96-99), there is a growing interest  in MSC 
treatment for ARDS.  Recently a phase 1 dose-escalation study demonstrated safety of a 
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single intravenous administration of 1 to 10 million cells/kg of MSCs in 9 patients with 
moderate to severe ARDS and a phase 2 trial is currently underway (114). 
 
 
ARDS criteria according to the Berlin definition 
Lung injury of acute onset, within 1 week of an apparent 
clinical insult and with progression of respiratory symptoms 
Bilateral opacities on chest imaging not explained by other 
pulmonary pathology 
Respiratory failure not explained by heart failure or volume 
overload 
PaO2/FiO2 ratio:  
mild ARDS: ratio 201 – 300 mmHg  
moderate ARDS: ratio 101 – 200 mmHg  
severe ARDS:ratio  ≤ 100 mmHg 
With a positive end-expiratory pressure (PEEP) ≥5 cm H2O 
Table 2. ARDS diagnostics according to the Berlin criteria 
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2 MATERIALS AND METHODS 
Ethical considerations.  
Project 1 was done under the ethical approval N310/08 and N309/08 for the use of labaratory 
animals. 
Project 2 was done under the etical approval S198-11  for the use of labaratory animals and 
propageting hESCs Dnr 454/02. 
Project 3 The production of clinical-grade MSC was accredited by the Swedish Board of 
Health and Welfare (Approval # 9.1-57237/2012) and the Medical Products Agency 
(Approval number: 5.9.2-2013-047346). ECMO is a last resort supportive therapy for ARDS. 
The patients in this report deteriorated on ECMO support and since the patients were sedated 
prior to MSC administration, informed consent could not be obtained. At a multidisciplinary 
conference the decision was made to use MSCs on a compassionate use basis under the 
approval of the chief medical officer of the hospital, the hospital ethics committee, and the 
relatives of the patients. A phase 1 trial is on the way with the ethical approval number DNR 
2013/1908-31/2 and Clinicaltrial.gov identifier NCT02215811,  
Paper I 
Synthesis of peptides.  
All peptides were synthesized using an automated peptide synthesizer (ABI433A; Applied 
Biosystems). N-terminally stearylated peptides were prepared by treatment of peptidyl-resins 
with 4 eq. stearic acid (Sigma) and 4 eq. HOBt/HBTU (MultiSynTech) and 8 eq. DIEA 
(Fluka). Peptides were purified by reversed-phase high-performance liquid chromatography. 
The molecular weight of the peptides was analyzed by matrix- assisted laser 
desorption/ionization-time of flight mass-spectroscopy and purity was >90% as determined 
by analytical high-performance liquid chromatography.  
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Cell culture. CHO cells were grown at 37 °C, 5% CO2 in Dulbecco’s modified Eagle’s 
medium F12 with glutamax supplement with nonessential amino acids, sodium pyruvate, 
10% fetal bovine serum, penicillin, and streptomycin (PAA Laboratories GmbH).  
HEK293, U87, U2OS and mouse embryonal fibroblast cells were grown at 37 °C, 5% CO2 in 
Dulbecco’s modified Eagle’s medium with glutamax supplemented with nonessential amino 
acids, sodium pyruvate, 10% fetal bovine serum, penicillin, and streptomycin (PAA 
Laboratories GmbH).  
Complex formation. 0.5 µg of pGL3 or pEGFP-C1 plasmid (4.7 kb), expressing luciferase or 
EGFP respectively, was mixed with CPPs at different peptide:plasmid CRs of 0.5:1–4:1 
(CR0.5–CR4) in milli-Q water in 50 µl (1/10th of the final treatment volume). CRs were 
calculated theoretically, taking into account the positive charges of the peptide and negative 
charges of the plasmid. Complexes were formed for 1 hour at room temperature. Meanwhile, 
cell medium was replaced in 24-well tissue culture plates for fresh media (450 µl). In case of 
LF2000 (Invitrogen), the complexes were formed according to the manufacturer’s protocol, 
using the recommended amounts for each cell line. Additional luciferase- expressing 
plasmids were used, namely pcDNA4/TO-Ubi-FFLuc (7kb) and pEGFPLuc (6.4 kb), both 
from Clontech.  
DNA condensation was analyzed using an EtBr (Sigma, Taufkirchen, Germany) exclusion 
assay. Briefly, complexes were formed as described above. After 1 hour incubation, 135 µl 
milli-Q water was added to each sample and transferred into a black 96-well plate (NUNC). 
Thereafter, 15 µl of EtBr solution was added to give a final EtBr concentration of 400nmol/l. 
After 10 minutes, fluorescence was measured on a Spectra Max Gemini XS fluorometer 
(Molecular Devices, Palo Alto, CA) at λex = 518 nm and λem = 605 nm. Results are given as 
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relative fluorescence and a value of 100% is attributed to the fluorescence of naked DNA 
with EtBr.  
Stability of stearyl-TP10/plasmid nanoparticles was evaluated in the presence of serum. 
Briefly, complexes were formed as described above. Thereafter, serum was added to the 
complexes at standard concentration (10%) and incubated over different periods of time. At 
0, 1, 2, 4, and 24 hours samples were loaded on an agarose gel (2%) and imaged by staining 
the gel with EtBr (0.5 µg/ml).  
Dynamic light scattering and zeta potential measurements.  
Hydrodynamic mean diameter of the DNA nanoparticles was determined by dynamic light 
scattering studies using a Zetasizer Nano ZS apparatus (Malvern Instruments). pDNA 
complexes resulting from the addition of stearyl-TP10 were formulated according to the 
protocol for in vitro transfection, as described above, and assessed in disposable low volume 
cuvettes. Briefly, pDNA complexes were formulated in deionized water, in 20 µl volume, at a 
final concentration of 0.01 µg/µl of pDNA. After 30 minutes incubation at room temperature, 
the DNA complexes were diluted in Opti-MEM into a final volume of 200 µl. All data was 
converted to “relative intensity” plots from where the mean hydrodynamic diameter was 
derived. æ-Potential was measured in Opti-MEM supplemented with 10% fetal calf serum. 
Measurements were performed in ZS Malvern instrument.  
Heparin displacement assay. 
 For the analysis of their resistance to heparin, peptide formulations containing 100 ng of 
pDNA were incubated for 30 minutes at 37 °C in the presence of heparin sodium (Sigma-
Aldrich) over a range of concentrations. After the incubation period, loading buffer was 
added and the reactions were analyzed on 0.8% agarose gels in 1× TAE buffer and visualized 
by staining with SYBR Gold (Invitrogen). Gels were documented using the Fluor-S system.  
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Plasmid delivery assay.  
CHO, HEK293, U87, U2OS, and mouse embryonal fibroblast cells were seeded 24 hours 
before experiment into 24-well plates. Cells were treated with CPP/plasmid complexes at 
different CRs for 4 hours in serum-free or serum containing media followed by addition of 1 
ml 10% serum containing medium and incubated for another 20 hours. Thereafter, cells were 
washed and lysed using 100 µl 0.1% Triton X-100 in HEPES-buffered Krebs Ringer buffer at 
room temperature. Luciferase activity was measured using Promega’s luciferase assay system 
on GLOMAX 96 microplate luminometer (Promega) and normalized to protein content 
(Lowry; Bio-Rad). LF2000 (Invitrogen) was used according to the manufacturer’s protocol 
and results were taken as a positive control for measuring transfection efficiency.  
In experiments with chloroquine, after complex formation and before treatment of cells, 
chloroquine was added to the complex solution. Four hours after addition of the complexes 
and chloroquine to cells, cell medium was replaced with fresh medium in order to avoid 
toxicity effects.  
Spectrofluorometry analysis. 
U2OS cells were seeded in 24-well plates 24 hours before cellular treatments with 
fluorescein-plasmid (Mirus) complexed with TP10 or stearyl-TP10 as described in the 
complex formation section. Cells were treated for 24 hours either in Opti-MEM or in 
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum. Cells were 
washed twice with phosphate-buffered saline and once, briefly, with trypsin to remove 
membrane-bound complexes. Cells were thereafter lysed using 0.2% Triton in phosphate-
buffered saline for 1 hour and lysates were transferred to a black 96-well plate. Fluorescence 
was measured on at 490/518 nm on a Spectra Max Gemini (Molecular Devices) fluorometer. 
Fluorescence signal (RFU) from untreated cells was subtracted from the signals of treated 
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cells.  
Confocal microscopy.  
CHO cells were seeded 24 hours before experiment onto 13 mm tissue culture coverslips that 
were placed into a 24-well plate. Cells were treated with pEGFP-C1 plasmid and CPP 
complexes at different CRs (1–3) for 4 hours in serum-free media followed by addition of 1 
ml of full growth media and incubated for another 20 hours at 37 °C. LF2000 (Invitrogen) 
was used according to the manufacturer’s protocol. Thereafter, cells were washed with 
phosphate-buffered saline and fixed by using 4% formaldehyde solution. Images were 
captured using 60-fold objective on Nikon Eclipse TE2000-U inverted microscope and a 
digital camera DXM1200C, and processed with EZ-C1 software V.2.30 (Nikon).  
WST-1 proliferation assay.  
Cell proliferation was studied with the Roche WST-1 proliferation assay according to the 
manufacturer’s instructions. Briefly, cells were seeded one day before the experiment in a 96-
well plate. Cells were treated with stearyl-TP10/plasmid nanoparticles at different CRs for 4 
hours in serum-free medium followed by addition of 10% serum containing medium and 
incubated for another 20 hours. Transfection with LF2000 was carried out according to the 
manufacturer’s protocol. WST-1 was added according to manufacturer’s protocol (Roche 
Diagnostics Scandinavia AB). WST-1 measures the activity of mitochondrial dehydrogenases 
to convert tetrazolium salts to formazan, which absorbs light at 450nm. Absorbance was 
measured on Digiscan absorbance reader (Labvision via AH Diagnostics AB). Untreated 
cells were defined as 100% viable.  
IL-1β, tumor necrosis factor-α , and IL-6 analysis.  
THP1 cells were differentiated using phorbol myristate acetate for 48 hours and subsequently 
seeded into 24-well plates. Cells were treated as previously. Lipopolysaccharide was used as 
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positive control. Culture supernatants were collected at 4 hours and 24 hours after treatment, 
and assayed for IL-1β and tumor necrosis factor-α by enzyme- linked immunosorbent assay 
according to manufacturer’s protocol (R&D systems). IL-6 and tumor necrosis factor-
α levels in blood were analyzed at 24 hours post i.d. or i.m. treatments of NMRI female mice. 
Blood was collected retro-orbitally and serum was purified using serum separation tubes (BD 
Bioscience). An amount of 100 µl serum was assayed using enzyme-linked immunosorbent 
assay Max Deluxe Set (BioLegend) and absorbance measured on Spectra Max Gemini 
(Molecular Devices).  
In vivo experiments.  
Female Balb/c mice were first anaesthetized with isoflurane gas and kept under anesthesia 
during the administration procedure. For the complex formation, 1, 5, or 10 µg of pGL3 (4.7 
kb) or pEGFPLuc (6.4 kb) plasmid was mixed with stearyl-TP10 at CRs of 0, 0.5, 1, and 2 in 
5% glucose using a total volume of 50 µl. In decay kinetics measurements 5µg of pGL3 
plasmid was used, while in dose-dependency experiments, the abovementioned doses of 
pEGF- PLuc plasmid was used. Thereafter, stearyl-TP10/plasmid nanoparticles were injected 
i.d. or i.m. into M. tibialis anterior. Gene expression was assessed by imaging of the reporter 
gene (firefly luciferase) expression. Anesthetized mice were injected intraperitoneally with 
150 mg/kg of D-Luciferin (Xenogen). Light signals (CCD) images were obtained using an 
IVIS 100 system (Xenogen). Luciferase expression was quantified by total flux using Living 
Image Software (Xenogen). The maximum photon/second of acquisition/cm2 pixel/steridian 
was deter- mined within a region of interest to be the most consistent measure for 
comparative analysis. In general, acquisition times ranged from 10 seconds to 1 minute.  
 
Clinical chemistry and histopathology.  
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Clinical chemistry parameters (alanine transaminase/aspartate transaminase, C-reactive 
protein, and creatinine levels) in serum from Balb/c mice were analyzed after 24 hours post-
treatments by the Clinical chemistry laboratory at Karolinska University Hospital using 
International Federation of Clinical Chemistry and Laboratory Medicine standardized 
techniques. Blood was collected retro-orbitally and serum was purified using serum 
separation tubes (BD Bioscience). Organs were dissected after 24 hours and fixed in 
formalin, embedded in paraffin, and stained with eosin and hematoxylin. Images were taken 
on the Olympus BX45 microscope with a Sony DXC-S500 digital camera. Histology sections 
were analyzed by the Department of Pathology at Karolinska University Hospital.  
Ethical permission.  
The animal experiments were approved by The Swedish Local Board for Laboratory 
Animals. The experiments were performed in accordance with the ethical permission and 
were carried out in accordance to European Community directive (86/609/EEC). All animal 
experiments were designed to minimize the suffering and pain of the animals.  
Statistics.  
Values in all experiments are represented as mean ± SEM of at least three independent 
experiments done in duplicate. Increase in delivery efficiency was considered significant at 
***P < 0.001 using analysis of variance Dunnett’s multiple comparison test or analysis of 
variance Bonferroni’s multiple comparison test. In toxicity measurements, decrease in 
viability was considered significant at ***P < 0.001 using analysis of variance Dunnett’s 
multiple comparison test.  
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Paper II 
Human ES and iPS cell cultures 
All the earlier established hES cell lines and the human iPS ChiPSW cell line were provided 
by Prof. Hovatta. CVTB1.2 cell line was provided by Dr. Hansson. hES cells and iPS cells 
were maintained in mTeSR1 (prepared in our laboratory or purchased from STEMCELL 
Technologies), TeSR2 (STEMCELL Technologies), and NutriStem hESC XF (Biological 
Industries, Israel) media as described in Supplemental Experimental Procedures. Matrigel 
(STEMCELL Technologies) and laminin-521 (LN-521) were used as cell attachment 
substrata. 
Cell culture dish coating 
Laminins and Matrigel.  
Tissue cell culture plates from Sarstedt were coated overnight at 4 °C with sterile solutions 
of laminins, such as human recombinant LN-521, all at a concentration of 30 µg/ml (5 
µg/cm2). Laminins were obtained from BioLamina AB and were produced as described in 
Supplemental Experimental Procedures. Control plates were coated with Matrigel 
according to the STEMCELL Technologies’ instructions.  
 
LN-521/E-cadherin coating.  
LN-521 and E-cadherin (R&DSystems) were taken at 9 to 1 w/w ratio with DPBS containg 
Ca2+ and Mg2+ used to dilute the proteins. Tissue culture plates were coated at +37 oC for 2 
hours at a concentration of 13.5 µg/ml (2.25 µg/cm2) LN-521 and 1.5 µg/ml (0.25 µg/cm2) 
E-cadherin. After that the plates were washed twice with DPBS containg Ca2+ and Mg2+ 
and, then, prewarmed stem cell medium of choice was added. 
Reagents and antibodies 
Function blocking antibodies to various integrin subunits, mouse isotype antibodies, and α-
 27 
dystroglycan were purchased from Millipore. Antibodies to Lutheran receptor and α-
fetoprotein, as well as rat isotype control antibodies were obtained from R&D Systems. 
Antibodies to Oct4, Nanog, SSEA-4, smooth muscle actin, and MAP-2 were purchased 
from Millipore. 
Immunofluorescence 
For immunofluorescence studies, ES cells were cultured and fixed by 4 % 
paraformaldehyde, permeabilized, and blocked by bovine fetal serum (GIBCO) for one 
hour. The samples were incubated with primary antibody washed 3-5 times, incubated with 
secondary antibody and 4,6-diamidino-2-phenylindole (DAPI, Molecular Probes), and 
washed 5 times. Specimens were preserved in a fluorescence mounting medium (Dako, 
Glostrup, Denmark), and observed under a fluorescence microscope (Leica). 
Real-time PCR quantification of different mRNAs 
Total RNA was isolated using Absolutely RNA Microprep Kit (Stratagene) according to 
the manufacturer’s instructions. cDNA was synthesized using total RNA in 20 µl reaction 
mixture, containing oligo(dT) primers and Superscript II reverse transcriptase (GIBCO 
Invitrogen). Real-time quantitative RT-PCR Taqman assays were performed using the 
Applied Biosystems 7300 Real-Time PCR System (Applied Biosystems). All reactions 
were done in quadruplicates with the use of pre-developed gene expression assay mixes 
(Applied Biosystems). Additional reactions for each experiment included pre-developed 
gene expression assay mix for GAPDH for normalizing the RNA input. 
FACS analysis 
Cells were removed from the culture dish with Trypsin/EDTA, dissociated into single cell 
suspension and resuspended in ice-cold FACS buffer. Incubation with primary antibodies 
against SSEA-4 (from Millipore) was performed for one hour on ice. Then, the cells were 
washed three times with ice-cold FACS buffer. Subsequently, the cells were probed in 
FACS buffer with 1:400 dilution of Alexa Fluor anti-mouse secondary antibodies (GIBCO) 
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for 30 minutes in the dark, and washed four times. Control cells were incubated with mouse 
immunoglobulins and, subsequently, with the secondary antibody as described above. Cells 
were analyzed on FACSCalibur Flow Cytometer. 
Karyotyping 
Karyotyping of the cell lines was carried out using standard Q-banding techniques. Samples 
of cells were treated with colcemid KaryoMAX (0.1 mg/ml; Gibco) for up to 5 h prior the 
procedure. A minimum of 10 metaphase spreads were analyzed and additional 20 were 
counted. 
In vivo imaging and migration assay 
The ES cells were plated onto extracellular matrix-coated plates and left to adhere for half an 
hour. After that, the plates were transferred into a high throughput imaging system (Operetta, 
PerkinElmer) equipped with an environmental control unit (37 °C, 5% CO2). The brightfield 
images were taken once in 30 minutes during several days after plating using Harmony 
software (PerkinElmer), exported, and analyzed using ImageJ software (NIH, the US).  
Teratoma formation 
Teratoma formation experiments were done by implantation of approximately 106 cells 
beneath the testicular capsule of a young (7-week-old) severe combined immunodeficiency 
(SCID) mouse or by injecting the cells subcutaneously in female SCID mice. The mice 
were sacrificed eight weeks after the implantation. The teratomas were fixed, and sections 
were stained with hematoxylin and eosin (HE) or with hematoxylin, eosin and PAS (HE-
PAS). All animal experiments were performed in accordance with the ethical committee’s 
approval. 
Embryoid body formation 
ES cells were scraped from cell culture dishes in large cellular clumps and cultured in 
suspension in low adhesion plates in Knockout DMEM (GIBCO) supplemented with  20% 
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fetal calf serum (GIBCO). After 1-2 weeks in suspension, the embryoid bodies were 
transferred onto gelatin coated plates, cultured for 1-2 weeks, then fixed, stained with 
antibodies against markers of all three embryonic germ line layers (smooth muscle actin, 
MAP-2 and α -fetoprotein), and analyzed as described above for immunofluorescence. 
Cell adhesion assay 
Multi-well plates were coated by extracellular matrix proteins as described above. The ES 
cells were plated onto extracellular matrix-coated plates and left to adhere for 1 hour. 
Subsequently, the plates were washed 3 times with the medium to remove the non-adherent 
cells, and then the adherent cells were fixed by 5% glutaraldehyde, stained by 0.1% Crystal 
Violet (Kebo Lab, Spanga, Sweden). After one hour and 3 washes with water, Crystal 
Violet was extracted with 10% acetic acid and quantified by measuring optical density at 
570 nm. All the experiments were performed in quadruplicates. 
Cell survival assays 
The survival assay was performed as described for the cell adhesion assay above, except that 
the cells were left in the cell incubator for 24 hours. For inhibition of the survival assay, the 
cells were kept in a medium with function blocking antibodies at the concentrations 
recommended by the manufacturer or pathway inhibitors at concentrations indicated in the 
text for 30 minutes, and then plated on the coated dishes. All the experiments were performed 
in quadruplicates.  
Western blotting and ELISA 
After two washings in ice-cold PBS, plates with cells were snap frozen in liquid nitrogen and 
stored at -80 °C. To prepare samples for western blots and ELISA, the plates were slowly 
thawed and kept on ice with 100-150 µl of lysis buffer and Phospho-StopTM (Roche)) on top. 
Then, the cells were scraped, pipetted, sheared through a 27G ¾” needle, and clarified by 
centrifugation. For western blots, 4-12 % gradient gels were used for SDS electrophoresis 
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and the proteins were transferred to PVDF membranes. The membrane was hybridized with 
the antibody of interest according to the manufacturer’s instructions. Chemoluminescent 
HRP-substrate was used for visualization. For the densitometry analysis the films were 
scanned at 2,400 dpi and analyzed by the ChemiImager5500 program. For ELISA the 
samples were applied to the wells according to the manufacturer’s instructions.  
Derivation of hES cell lines from whole ICMs of blastocysts 
The embryos for derivation of new ES cell lines were obtained as donations from the Fertility 
Unit of Karolinska University Hospital, Huddinge. Only embryos that could not be used for 
the couples’ infertility treatment were used after informed consent given by both partners of 
the couples. The work was done in accordance with ethics approval for derivation of new 
human ES cell lines issued to us by the Regional Ethics Board in Stockholm.  
Day 5-7 blastocysts donated after informed consent of both donors, were scored and 
transferred to TESR2 (Stem Cell Technologies) or NutriStem hESC XF medium. The inner 
cell masses (ICMs) were isolated mechanically using two sharp metal needles (ICM-tools 
were made of tungsten, provided by Hunter Scientific, Essex, UK). Then, the ICM was 
placed on LN521/E-cadherin matrix in a 20 µl drop of TESR2 (supplemented with 20 mg/ml 
of recombinant human albumin) or NutriStem hESC XF medium, under oil. After the 
derivation, the cells of new lines were passaged mechanically several times. After the 
adaptation period, the cells were passaged using the standard procedure of this study, i.e. in 
single cell suspensions. 
Derivation of new hES cell lines from single blastomeres 
The work was done in accordance with ethics approval issued to us by the Regional Ethics 
Board in Stockholm. The donated cleavage stage embryos, frozen two days after in vitro 
fertilization, were thawed and cultured for one more day. Single blastomeres were biopsied in 
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droplets of 30 µl biopsy medium G-PGD (Vitrolife) under mineral oil. For a biopsy, the 
embryo was fixed by a holding pipette, and the zona pellucida (ZP) was pierced gently using 
a Saturn laser (Research Instruments, Ltd, Cornwall, United Kingdom). Once blastomere was 
acquired, immediately transferred to droplets containing fresh culture medium to be rinsed 
one time and, after that, placed on LN-521/E-cadherin matrix in a 20 µl drop of medium 
under oil. 
SNP 6.0 array 
Copy number variations (CNVs) and copy-number neutral loss-of-heterozygosity (LOH) 
regions were analyzed using Affymetrix Genome-Wide Human SNP Array 6.0 array and 
Genotyping Console Software version 4.1 (Affymetrix). The analysis was done using 
default parameters and comparing each sample against a reference set of 75 healthy 
individuals generated earlier in the same lab for a different project. The minimum size of 
CNV segments was 5 markers and 50 kb. Segments with 100% overlap with known CNV 
regions (according to the Toronto Database of Genomic Variants) were removed from the 
depicted results. 
 
Statistics 
Statistical significance was determined the by Student’s two-tailed t-test for unequal 
variances. 
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Paper III 
Clinical outcome measures 
Blood was collected as standard practice during routine care in the intensive care unit. 
Bronchoalveolar lavage (BAL) fluid was obtained from lavage performed at intervals as part 
of the routine clinical care provided to each patient. Blood samples for cell purification were 
collected in heparinized tubes. Serum and plasma samples for cytokines and extracellular 
vesicles were collected and frozen immediately after sample preparation and stored in -80 ºC 
until analyzed. Chest X-rays (CXRs) and chest computerized tomography (CT) scans were 
done as part of the routine clinical care provided to each patient.  Respiratory measurements 
including lung volumes and pressure were obtained from the mechanical ventilation record 
for each patient.  Other standard laboratory measurements were made as part of routine care 
for each patient and obtained from the patient’s record.  
BAL Fluid and serum analyses 
Levels of pro- and anti-inflammatory cytokines in serial samples of BAL fluid and serum 
were assessed using a multiplex cytokine assay (Millipore) on a Luminex machine 
(Millipore). In BAL fluid, surfactant protein B concentration was determined by enzyme-
linked immunosorbant assay (ELISA) (Uscn Life Science Inc). Caspase-cleaved K18 
(ccK18) and total K18 were measured using M30-Apoptosense® ELISA (Peviva AB) and 
M65 EpiDeath® ELISA (Peviva AB), respectively.  
Assessment of circulating miRNAs 
Inhibitory miRNAs were isolated from circulating extracellular vesicles (EVs) purified from 
the routine blood samples collected. EV purification and miRNA isolation were performed by 
Exosome Diagnostic Inc. In brief, 1.5-2 ml of blood sample from each time point was 
purified using the exoRNeasy serum/plasma kit (Qiagen). The eluted RNA was processed for 
microRNA analysis using the Low Sample Input protocol for the TaqMan® OpenArray® 
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Human MicroRNA Panel (Life Technologies). Megaplex™ RT Primers, Human Pool A and 
Human Pool B were used for reverse transcription followed by a pre-amplification step 
according to manufacturer’s protocol. Samples were loaded onto OpenArray® plates using 
the standard Accufill™ protocol.  Amplification was performed according to the protocol 
established for the TaqMan® OpenArray® Human MicroRNA panel downloaded for each 
plate (OpenArray Plate product page at www.lifetechnologies.com). In total 758 miRNAs 
were assayed and 200 to 300 miRNAs gave a detectable CT value for each time point. U6 
snRNA (non-coding small nuclear RNA) was used for normalization of miRNA.   
Mononuclear cell collection, cell purification, and In Vitro mixed lymphocyte studies 
Peripheral blood mononuclear cells (PBMCs) used in in vitro studies were retrieved from the 
patients and from healthy donors, isolated by density gradient-based centrifugation, and 
stored in 10% DMSO in liquid nitrogen until further analysis. For further purification of T-
cells, a paramagnetic bead-based selection was utilized (Miltenyi Biotec). The same BM-
MSCs as utilized in the patient were co-cultured with allogeneic T-cells. T-cells were 
stimulated with activating anti-CD2/CD3/CD28 antibodies (Miltenyi Biotec). PBMCs were 
cultured for five days in the presence of MSCs and the monocytic compartment was 
subsequently analyzed. Polymorphonuclear leukocytes (PMNs) from buffy coats of healthy 
donors were ultra-purified under endotoxin-free conditions. PMNs (> 95% purity) and MSCs 
were co-cultured for up to 40h in presence or absence of LPS (Invitrogen). In all cases, MSCs 
were plated 72 hours before the start of co-cultures. In selected experiments, MSCs were pre-
treated with recombinant human IFN-γ (Peprotech Rocky Hill), and TNF-α (R&D Systems), 
and finally co-cultured with freshly isolated PMNs. MSC and PMN co-cultures were stained 
with May Grünwald-Giemsa dye to observe cell morphology following reciprocal interaction. 
In Vitro Polymorphonucelar Cell (PMN) Assessments 
PMNs were stained according to the manufacturer’s instruction with fluorochrome-coupled 
antibodies. The LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit (Life technologies) was 
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used for the exclusion of dead cells for PBMC analysis, and propidium iodide (PI) 
(Invitrogen) staining for testing the viability of MSCs. For performing intracellular staining, 
cells were treated with the BD Cytofix/Cytoperm Fixation/Permeabilisation Kit (BD 
Biosciences). After co-culture with MSCs, PMNs were identified on the basis of their typical 
morphological parameters (forward scatter/side scatter) and their CD45 expression. An 
Annexin-V-FITC staining kit (Miltenyi Biotec) was used to assess the levels of PMN 
apoptosis. Cells were analyzed using a FACS Canto II cytometer (BD Biosciences) and 
FlowJo Version 9·5 software (TreeStar). 
RNA preparation and quantitative RT-PCR 
Total RNA was extracted (RNeasy mini kit; Qiagen) and cDNA prepared (Superscript First 
Strand Synthesis System, Life Technologies) using a Mastercycler nexus (Eppendorf). For 
cDNA transcription a two-step procedure was performed in line with the manufacturer’s 
recommendations. Messenger RNA levels were quantified by qPCR (Quantitect SYBR 
Green PCR Kit; Qiagen) on a Rotor Gene Q (Qiagen). Relative gene expression was 
determined by normalizing to the expression of beta2-microglobulin gene.  
In Vitro MSC responses to inflammatory stimuli 
The MSCs were tested in vitro for their responsiveness towards inflammatory stimuli (“MSC 
licensing”). Culture in the presence of TNF-α (15 ng/mL) or IFN-γ (10 ng/mL) for 48h 
induced the expression of CD54 (ICAM-1), CD106 (VCAM-1) and HLA-ABC and –DR, as 
assessed by flow cytometry, and indoleamine-2,3-dioxygenase (IDO) mRNA transcripts was 
measured by quantitative PCR . 
MSC EV purification  
MSCs were cultured in serum-reduced medium (OptiMem, Gibco) for 48 hours. The 
conditioned medium was harvested and spun and filtered through 0.2 µm sterile syringe 
filters to remove cell debris. The EVs were subsequently pelleted by ultracentrifugation. The 
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pellets were re-suspended in PBS, pooled and ultra-centrifuged. The remaining pellet was re-
suspended in PBS. Nanoparticle tracking analysis (NTA) was performed using the NS500 
(NanoSight, United Kingdom) to measure the size distribution of particles, which is based on 
the motion and light-scatter of nanometer-sized particles (Brownian motion). The number of 
particles and their movement were recorded using a camera level of 15 and automatic 
functions for all post-acquisition settings except for the detection threshold, which was fixed 
at 6. The samples were diluted in PBS between 1:500 to 1:2,000 to achieve a particle count of 
between 2 x 108 and 2 x 109 per ml. The camera focus was adjusted to make the particles 
appear as sharp dots. Using the script control function, 5x30 seconds videos were recorded; 
incorporating a sample advance and a 5 seconds delay between each recording and analyzed 
using the NS500 software. The EVs were frozen at -80 C until further analysis.  
EV preparation for proteomic assessment 
Donor cell pellet and EVs were lysed with 4% SDS, 25 mM HEPES, 1 mM DTT. Lysates 
were heated to 95°C followed by sonication and centrifugation. The supernatant was mixed 
with 1 mM DTT, 8 M urea, 25 mM HEPES, pH 7.6 and transferred to a centrifugation 
filtering unit, 10 kDa cutoff (Pall, Nanosep®), and centrifuged, followed by another addition 
of the 8 M urea buffer and centrifugation. Proteins were alkylated by 50 mM Indole-3-acetic 
acid, in 8 M urea, 25 mM HEPES for 10 min, centrifuged, followed by 2 more additions and 
centrifugations with 8 M urea, 25 mM HEPES. Trypsin (Promega), 1:50, trypsin:protein, was 
added to the cell lysate in 250 mM urea, 50 mM HEPES and incubated overnight at 37 °C. 
The filter units were centrifuged, followed by another centrifugation with MilliQ water and 
the flow-through was collected. Peptides were cleaned by a strata-X-C-cartridge 
(Phenomenex).  
NanoLC-MS/MS analysis 
Before analysis of the Q Exactive mass spectrometer (Thermo Fisher Scientific), peptides 
were separated using an Agilent 1200 nano-LC system. Samples were trapped on a Zorbax 
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300SB-C18, and separated on a NTCC-360/100-5-153 (Nikkyo Technos., Ltd) column using 
a gradient of A (5% DMSO, 0.1% Formic Acid) and B (90% Acetonitrile, 5% DMSO, 0.1% 
FA), ranging from 5 % to 37 % B in 240 min with a flow of 0.4 µl/min. The Q Exactive MS 
was operated in a data dependent manner, selecting top 5 precursors for fragmentation by 
Higher Energy C-trap Dissociation (HCD). The survey scan was performed at 70,000 
resolutions from 300-1700 m/z, with a max injection time of 100 ms and target of 1 x 106 
ions. For generation of HCD fragmentation spectra, a max ion injection time of 500 ms and 
AGC of 1 x 105 were used before fragmentation at 30% normalized collision energy, 35,000 
resolutions. Precursors were isolated with a width of 2 m/z and put on the exclusion list for 70 
s. Single and unassigned charge states were rejected from precursor selection.  
Peptide, protein identification and data Analyses 
Proteome discoverer 1.4 with sequest-percolator was used for protein identification. 
Precursor mass tolerance was set to 10 ppm and for fragments to 0.02 Da. Oxidized 
methionine was set as dynamic modification, and carbamidomethylation as static 
modification. Spectra were matched to a combined database of Uniprot human (140203) 
combined with the 250 most abundant proteins from 4h nLC-MS/MS analysis of FBS (Bos 
taurus, uniprot 140203), and results were filtered to 1% FDR. Identifications in bos taurus 
was considered to originate from FBS and removed. GO term enrichment analysis was done 
using Panther (115). 
Statistical Analyses 
Wilcoxon paired test was used to compare the differences between two different groups. One-
way ANOVA analysis was used to statistically evaluate the difference of sample means 
among multiple groups. Significant level was set at a p-value <0.05. 
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3 AIM, RESULTS AND DISCUSSION 
 
Aim  
The general aim of this thesis was to develop gene and cell therapy methods for the use in 
regenerative medicine. Paper I and II are preclinical work investigating fundamental aspects 
of gene transfer and cell culturing methodology that could be implemented into clinical 
protocols in the future. Paper III is a case report describing translational cell treatment in 
patients with ARDS. 
 
Specific aims. 
Paper I. To study the in vivo and in vitro properties of a novel peptide conjugate and elaborate 
on mechanisms for improved uptake. 
Paper II To produce a protocol for xeno-free derivation of human embryonic stem cells. 
Paper III To describe the clinical course in patients with severe ARDS on ECMO and to 
correlate the clinical outcome to in vitro mechanistic parameters. 
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Paper I: A Peptide-based Vector for Efficient Gene Transfer In Vitro and In Vivo  
In this paper we investigated the use of stearyl-TP10 peptide for delivery of plasmid DNA in 
cell culture and in mice using intra muscular and intra dermal delivery. The aim was to 
combined a functional cell penetrating peptide, TP10, with stearyl to enhance endosomal 
escape. Endosomal escape has been a bottleneck for plasmid delivery and several methods 
has been described to overcome this problem (116, 117). By adding the stearyl moiety to the 
TP10 peptide we could increase the expression of plasmids in cell culture up to 4 logs in 
comparison with naked plasmid delivery (Fig. 2b 3a, b, d and 4b). The mechanism has not 
fully been investigated, but the increased expression could be attributed to effective 
condensation (Fig 1b, Table 1) resulting in protection against degradation (Fig 1c-e). 
Fluorescently labeled plasmid uptake was equal between TP10 and Stearyl-TP10 groups (Fig 
2e) in absence of serum and the expression of the TP10/plasmid could not be enhanced by the 
endosomolytic agent chloroquine (Fig 2a). This data supports that endosomal escape might 
not be the predominant mechanism.  One hypothesis could be that the lack of effect of 
TP10/plasmid could be rapid dissociation of peptides from plasmids in presence of serum 
or the endosomal environment prohibiting either cell entry or yielding degradation in the 
endosome. This argument is supported by TP10 inability to promote plasmid uptake in 
presence of serum and that heparin dissociates the TP10/plasmid complexes showing that 
these complexes are very labile (Figures 2f and 1e). Addition of forms more stable particles 
with plasmids and protecting the DNA from degradation.  
We could also demonstrate charge dependent as well as dose dependent intra muscular and 
intra dermal uptake in mice (Fig 5 a-d). The increase in plasmid expression was only seen in 
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with charge ratio 1:1 plasmid:TP10-stearyl. These findings show the importance of 
condensation of plasmid for in vivo delivery. Too low charge ratios do not improve on 
plasmid transfection in vivo. Too high charge ratios yield condensed nanoparticles hampering 
either uptake or expression in the nucleus of the plasmid. These results are corroborated by 
the inability of heparin to displace peptide from the nanoparticle at high charge ratios. Since 
transfection efficacy increased with higher charge ratios in vitro, the main cause could be due 
to different mechanisms of cellular uptake in vitro and in vivo rather than intracellular events. 
These findings of the relevance of charge ratio for efficient in vivo gene transfer and the poor 
correlations of in vitro and in vivo results have been discussed in other publications (118, 
119).  
This study has several limitations. There is no control for TP10/plasmid nano particle in vivo. 
The reasoning was to only test the favorable constructs in the in vitro assays in vivo. But, as 
explained above, since in vitro data can correlate poorly to the in vivo data this control could 
have been valuable. Furthermore there are only basic toxicity assessments and this should be 
developed before possible clinical use. Although not the aim of the paper, the use of stearyl-
TP10 as a transfection agent for siRNA could be beneficial, since the basic mechanism is to 
promote endosomal escape. The use of stearyl-TP10 peptide in combination with siRNA has 
since been demonstrated in model system for cochlear cultures (120) . 
 
Paper II: Clonal culturing of human embryonic stem cells on laminin-521/E-cadherin 
matrix in defined and xeno-free environment 
In this paper we investigated natural conditions that allow clonal survival of hPSCs and 
derivation of new hESC lines under xeno-free and chemically defined conditions. As 
described above, laminins are important class of extracellular matrix (ECM) proteins. All the 
laminin isoforms that are expressed in hPSCs were produced as recombinant proteins, used as 
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cell culture substrata and were tested with regard to their ability to support self-renewal of 
hPSCs. Only LN-521 and LN-511, which had been previously shown to facilitate self-
renewal of hPSCs (59), allowed attachment and proliferation of hPSCs. Laminin-521, unlike 
LN-511, also allowed efficient survival and proliferation of individual hPSCs plated at 
densities higher than 5 000 cells per cm2. Time-lapse imaging of living cells and analysis of 
actin-myosin rearrangements demonstrated that LN-521 induced higher motility of hPSCs in 
comparison with other tested cell culture substrata and that the cells on LN-521 survived 
through fast migration to each other. Culturing of hPSCs on LN-521 provided much faster 
multiplication of hPSC number with time than that on other tested ECM proteins. The easy 
and robust methods described in the paper allow efficient self-renewal of hPSCs under xeno-
free and chemically defined conditions and may be useful for development of cell lineages 
aimed at clinical application in the future. 
Individualized hPSCs plated at cloning density (less than 1 000 cells per cm2) die from 
anoikis (121) that is a form of apoptosis. Cadherin and ECM mediated signaling is capable to 
prevent anoikis. In the paper we tested cell adhesion substrata composed of various ECM 
molecules and E-cadherin that is abundantly expressed on the hPSC membrane. A mixture of 
LN-521 and E-cadherin (taken at 9:1 w/w ratio) allowed efficient clonal survival of hPSCs. 
Cloning of hPSCs may be useful for many scientific and medical applications, e.g. it may 
facilitate manipulation of the human iPSC genomes to repair genetic mutations.  
Although many methods allowing self-renewal of hPSCs under xeno-free and chemically 
defined conditions have been published to date (59-61, 122), no such methods for derivation 
of new hESC lines have been reported until very recently. This paper described an efficient 
procedure that facilitated derivation of new hESC lines under fully xeno-free and chemically 
defined conditions both from the inner cell masses of blastocysts and from single 
blastomeres. The latter may allow derivation of new hESC lines without destruction of a 
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parental embryo addressing an important ethical concern of many. Human ESCs are already 
used in medicine and still considered as “gold standard” pluripotent cells (40). Free from the 
ethical dilemma and developed in fully defined environment hESCs may significantly 
facilitate clinical treatments involving them.  
 
Paper III In vivo effects of mesenchymal stromal cells in two patients with severe acute 
respiratory distress syndrome  
This paper describes the use of allogeneic transplantation of mesenchymal stromal cells in 
two patients with severe ARDS on ECMO support. Since this is a small case series the 
therapeutic benefit can only be speculated. Progressive clinical improvement could be seen 
shortly after the infusion of the cells. Improvement of lung function in both patients was 
demonstrated by increased compliance, tidal volume as well as chest X-rays. The clinical 
improvement continued and both patients were successfully weaned off ECMO (Fig 1 and 2). 
The paper also demonstrates the feasibility of administration of MSCs into the right atrium 
through a venous cannula during ECMO support. Apart from pneumonia in patient 1 that 
could be due to MSC treatment no advert events were seen.  The range of improvements in 
the in vivo inflammatory indices was broad. Decreases in multiple markers of inflammation, 
including markers of epithelial apoptosis, and proinflammatory cytokines, miRNAs, and 
chemokines in plasma and BAL fluid could be seen (Fig 3 a-e). Although the relevance of 
specific molecules are not clear in ARDS they could play an important role for restoring an 
energy deficit in the ARDS-injured lung, and restoring normal surfactant production. Another 
interesting finding was that the the nosocomial pneumonia in patient 1 could be detected not 
only by traditional markers but also by miRNA profiles in the extracellular vesicles (3e). This 
is another interesting field were one can use miRNA in diagnostics of inflammation. The 
paper also tries to outline assays to correlate in vivo to in vitro data. This is exemplified in 
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Figure I-J, where correlation could be seen in MSCs’ ability of Treg induction, which could 
be observed both in vitro and in vivo. Although Treg induction is slow and cannot explain the 
rapid improvement in clinical status it demonstrates that a MSC effect correlates well in both 
settings. In the in vitro experiments, we mimicked in part an inflammatory environment by 
pretreating the ex vivo expanded MSCs with IFN-γ and TNF-α  assess MSCs’ immune 
modulatory potency. This can be used as a preclinical batch controls test of MSC before 
administration.  No in vitro tests can be used as a perfect biomarker of in vivo behavior of 
MSCs. However, the combination of different in vitro standardized tests could possibly be 
used to increase the correlation of in vitro and in vivo data. The paper provides a baseline 
characterization of successfully used MSCs and also their extracellular vesicles. This 
information could be important for understanding the molecular determinants of functional 
cell batches of MSCs for clinical use in ARDS. In a similar fashion the experiments showing 
induction of regulatory phenotypes in monocytes, and neutrophils could if demonstrated 
consistent in more preclinical as well as in clinical trials to be of value to not only to 
understand the mechanism of MSC but also to get a deeper knowledge of the ARDS 
pathology.  
The paper has limitations in that this is only a small case series and larger clinical trials are 
needed to support these findings. Furthermore, the study has no control group so causal 
improvement can only be speculated upon. These limitations will be addressed in a future 
clinical study currently on the way. The paper has not penetrated a clear mechanism for the 
MSCs but many of the therapeutic effects of MSCs in ARDS are likely mediated by the 
release of soluble proteins and extracellular vesicles that contain a range of bioactive 
molecules. These molecules have been described in order to develop clinical protocols where 
more mechanistic questions are addressed. Since the pathology of ARDS is not fully 
understood it can be difficult at this point to draw to vast conclusions from the mechanistic 
work in the paper. When it comes to the cytokine, extracellular vesicle, as well as the cellular 
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data in the paper, it is hypothesis generating and need to be further explored in larger 
numbers of patients. From the clinical point of view, our data contrasts with those observed in 
a recent study of the administration of non-HLA-matched allogeneic adipose derived MSCs 
in ARDS patients. Although this study showed short-term improvement in oxygenation after 
MSC administration, there was no improvement in ventilator-free days, ICU-free days, or 
length of hospital (123). Another recently published safety study has shown that MSCs are 
well tolerated and safe but due to small study population no significance in secondary 
outcome measure was detected. In comparison to expected outcome in the moderate ARDS 
group, mortality was reduced from 32% to 22% but statistically not significant (114).  
Difference in outcome could be dependent on cell source, but also due to culture methods. 
Another possibility is that the differences are related to serendipity due to the small studies 
presently available.  
 
Concluding remarks and future challenges 
Regenerative medicine is a multidisciplinary field that is constantly evolving. Both gene and 
cell therapies are modalities that can be used in order to achieve regeneration of lost organ 
function. In both areas there has been a long and cumbersome process for successful 
implementation into the clinic. Novel medical therapies are usually delayed because of safety 
issues. Although time consuming, they play a pivotal role in drug development. In retrospect, 
many early clinical trials that have been carried out prematurely have rather slowed down the 
development than contributed to clinical implementation. Currently the use of gene therapy in 
the clinic as standardized therapies is on the way. Also, robust clinical trials using novel 
cellular therapies are under way. Traditionally gene and cell therapies have been separate 
research fields but several applications are on the way were the two fields merged.  
Gene transfer in combination with stem cell therapy is clearly a treatment for the future (124, 
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125) . Currently gene transfer vectors for the creation of iPSCs as well as vectors for iPSC 
and ESC differentiation are hot topics. Vectors are also used for modifying the stem cell or its 
derived differentiated cell to provide an additional phenotype. An example of this is the use 
of autologous genetically modified epidermal stem cells transplanted in patients with 
Junctional Epidermolysis Bullosa (126). Other interesting approaches are the use of 
bioengineered tissue for transplantation (127).  In this emerging field his thesis has outlined 
technologies that can be combined to the development of new strategies. A modification of 
the protocol in paper II is currently being assessed for culturing of mesenchymal stromal 
cells. One of the factors that is important for the efficacy of MSC treatment is the number of 
passages. The use of matrix molecules as well as soluble factors could potentiate the self-
renewal capacity and increase the number of passages with retained immunomodulatory 
properties. A recent report demonstrated promising results in treating ARDS with interferon-
beta-1a (128). The use of genetically modified MSCs with interferon-beta-1a could potentiate 
the treatment effect. Apart from development of new interesting combinatorial treatments, 
larger studies are needed to demonstrate robust efficacy of MSCs in the clinic. A phase I/II 
study is currently on the way in the USA and we are developing a phase I clinical trial with 
treatment of severe ARDS on ECMO support. Another challenge in cell and gene therapies is 
to correlate in vitro and in vivo data. Both papers I and III try to address these problems. 
There is a substantial need for in vitro assays were that predict robust in vivo results. 
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